Beam Therapeutics

$86.91
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$5.39 (-5.84%) As of 6:22 PM UTC today

Why Robinhood?

You can buy or sell BEAM and other stocks, options, and ETFs commission-free!

About BEAM

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA. The listed name for BEAM is Beam Therapeutics Inc. Common Stock.

CEO
John Evans
Employees
118
Headquarters
Cambridge, Massachusetts
Founded
2017
Market Cap
4.64B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.34M
High Today
$92.00
Low Today
$84.69
Open Price
$89.92
Volume
885.99K
52 Week High
$126.90
52 Week Low
$13.00

BEAM Earnings

-$1.03
-$0.69
-$0.34
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 23, Pre-Market

You May Also Like

VMW
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure